Cyclo Therapeutics (NASDAQ:CYTH) Now Covered by Analysts at Ascendiant Capital Markets

Ascendiant Capital Markets began coverage on shares of Cyclo Therapeutics (NASDAQ:CYTH) in a report issued on Monday morning, Benzinga reports. The brokerage issued a buy rating and a $2.60 target price on the stock.

Cyclo Therapeutics Stock Performance

Shares of CYTH stock opened at $1.26 on Monday. Cyclo Therapeutics has a 52 week low of $0.68 and a 52 week high of $2.57. The stock has a market capitalization of $36.18 million, a PE ratio of -0.96 and a beta of -0.15. The stock’s fifty day moving average is $1.51 and its 200-day moving average is $1.46.

Cyclo Therapeutics (NASDAQ:CYTH) last issued its quarterly earnings results on Monday, March 18th. The company reported ($0.23) earnings per share (EPS) for the quarter. The company had revenue of $0.31 million for the quarter. Cyclo Therapeutics had a negative return on equity of 4,506.97% and a negative net margin of 1,864.03%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cyclo Therapeutics stock. Founders Fund V Management LLC bought a new position in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 480,708 shares of the company’s stock, valued at approximately $764,000. Cyclo Therapeutics comprises approximately 80.8% of Founders Fund V Management LLC’s portfolio, making the stock its biggest position. Founders Fund V Management LLC owned approximately 2.11% of Cyclo Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 68.55% of the company’s stock.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.